Funding Details
- Awarder
- StartEngine
- Date Award
- June 13, 2024
- Vertical
- Biotech
- Funding URL
- View Funding Page
- Premoney Valuation
-
$59,840,000
- Valuation
-
$59,840,000
Company Info
- Founding Year
- Not provided
- Traction
- Deverra’s lead clinical asset, Dilanubicel, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. They are just one clinical trial away from potential FDA approval.
- Organizations Involved
- None
- Founders
- Michael Yurkowsky, Colleen Delaney, Andrew “Al” Kucharchuk
- Company Description
- Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.
- Market
- Healthcare
- Location
-
Seattle,
WA,
US
- Coinvestors
- None
Links